---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035331"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:11:34.835015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss

## Summary
- Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.
- Net income $259K ($0.01 diluted EPS) compared to net loss of $59K ($0.00) in prior year.
- Two largest customers represented 85% of revenue (down from 91%), reflecting diversification.
- No forward guidance or dividend changes were provided in the release.

## SEC filing metadata
- accession: 0001437749-24-035331
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774924035331/0001437749-24-035331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774924035331/inbp20241112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035331
- JSON: https://secwatch.observer/filing/0001437749-24-035331.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.